• Arbeitsgruppenleiter:in: PD Dr. Maja Tomičić-Christmann

• Forschungsschwerpunkte:
  
  Zellantworten auf gentoxischen Stress (HGG, CRC)
  
  Inhibitors of apoptosis proteins (Survivin & c-IAP1/2) und Gegenspieler (XAF1)
  
  DNA-Reparatur / Seneszenz-Escape-vermittelte Zytostatika-Resistenz in Glioblastomen
  
  Epigenetische Regulation durch Methylierung
  
  2D-Zelllinien, 3D-Glioblastom-Organoid-Modell
  
  Primärtumore versus Rezidive

• Fünf wichtigste Publikationen: 
  
  Aasland D et al. (2019) Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-kappaB. Cancer Res 79, 99- 113.
  
  Tomicic MT et al. (2019) Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6. ATOX 93, 2265-2277.
  
  Steigerwald C et al. (2018) Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53. ATOX 92, 2645-2648.
  
  Reich TR et al. (2017) Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget 8, 15071-15084.
  
  Tomicic MT et al. (2010) Topotecan triggers apoptosis in p53- deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther 332, 316-325.

• Ansprechpartner:in:
  
  PD Dr. Maja Tomičić-Christmann
  E-Mail: tomicic@uni-mainz.de